Skip to main content
. 2021 May 21;11:609548. doi: 10.3389/fonc.2021.609548

Figure 2.

Figure 2

p62 and LC3B protein expression as determined by immunohistochemistry assay. (A, B) High p62 (A, scale bar 100µm) and LC3B (B) expression at magnification ×100 (left) and ×200 (right). (C, D) Low p62 (C) and LC3B (D) expression at magnification ×100 (left) and ×200 (right). (E, F) High p62 expression was associated with shorter progression-free survival rates (E) and overall survival rates (F) in patients with bone metastasis of lung adenocarcinoma.